Eli Lilly & Co. (NYSE: LLY) won a ruling Wednesday that its patents for its Evista osteoporosis treatment are valid, according to Bloomberg.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The ruling will block an attempt by Teva Pharmaceutical Industries Ltd. to sell a generic version of the bone-loss drug.
U.S. District Judge Sarah Evans Barker in Indianapolis, in a ruling Wednesday, barred Teva from selling the drug in the U.S. before Eli Lilly’s patents have expired. The judge in April temporarily barred Teva from launching its product until she reached a final decision.
The ruling provides protection for Evista through March of 2014, Eli Lilly said in a statement. Evista, in which the key ingredient is raloxifene, generated $1.08 billion in global sales last year, the company reported Jan. 29. That includes $700.5 million, or an average of almost $2 million a day, in the U.S.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
